FDA Clears Cuprina's MEDIFLY Maggots, First Lucilia cuprina Product for Wound Debridement
CUPR has more than doubled off its 52-week low of $1.76 on elevated volume (50× avg).
Summary
Cuprina Holdings secured U.S. FDA 510(k) clearance for its MEDIFLY Maggots, marking the first U.S. approval for a Lucilia cuprina maggot debridement product. This significant regulatory win allows the company to commercialize the medical-grade larvae for non-healing wound debridement in the U.S. market. The clearance follows a challenging period where Cuprina completed a reverse stock split to regain Nasdaq compliance and reported increased losses. This approval is a crucial step towards generating new revenue and strengthens Cuprina's unique position as the only company holding commercial rights to both maggot species used in debridement therapy. The company plans to make the product available to U.S. wound-care providers and pursue international registrations.
At the time of this announcement, CUPR was trading at $6.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7M. The 52-week trading range was $1.76 to $76.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.